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OBJECTIVES: This study aimed to model the cost-effectiveness
of pre-hospital compared with in-hospital thrombolysis for
ST-elevation myocardial infarction (STEMI) from the Brazilian
National Health System perspective. METHODS: A decision-
analytic model was used to model these two strategies. Study
endpoint was life-years gained. Resources use and costs were
estimated from the National Health System perspective. Decision
tree and Markov Model were constructed using the results from
published clinical trials. Costs were applied in Real (R$), 2005
year values. RESULTS: At the time horizon of 20 years, pre-
hospital thrombolysis had an average life expectancy of 11.48
years and in-hospital thrombolysis had an average life expect-
ancy of 11.32 years. Total costs were R$ 5640 for pre-hospital
thrombolysis and R$ 5816 for in-hospital thrombolysis. In-
hospital thrombolysis led an additional cost of R$ 176 per
patient. Pre-hospital thrombolysis led an additional 0.15 years of
life-expectancy gained compared with in-hospital thrombolysis.
CONCLUSION: This model suggests that, from National Health
System perspective, implementing pre-hospital thrombolysis for
ST-elevation myocardial infarction (STEMI) may lead to extra
survival and less cost than in-hospital thrombolysis.
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SECONDARY PREVENTION
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OBJECTIVES: The purpose of this study was to estimate the
cost-effectiveness comparing high dose Atorvastatin (80 mg) to
standard dose Pravastatin (40 mg) in secondary prevention
setting in Sweden. METHODS: Two-year event rates from
PROVE-IT, where 4162 patients who had been hospitalized for
acute coronary syndrome (ACS) within 10 preceding days were
randomized to either 80 mg Atorvastatin (A80) or 40 mg Prav-
astatin (P40), was used to estimate cost-effectiveness comparing
the lipid lowering therapies. Primary endpoints were death, myo-
cardial infarction, unstable angina, revascularization or stroke.
Costs were given in SEK (2006 price level: 1 EURO = 9.329 SEK)
and measured as unit costs for primary endpoints and drug costs.
RESULTS: Due to fewer events in the A80 arm (622 compared to
739), event costs were considerable lower (40,915,253 SEK)
compared to the P40 arm (47,518,042 SEK). The average total
cost per patient over 2-years was 29,566 SEK in the A80 arm
compared to 24,327 SEK in the P40 arm. The cost per event
avoided by treating patients with A80 compared to P40 was
93540 SEK. The cost per life year gained (LYG) was 51092 SEK.
Given an 80% increase/decrease in the price of P40 cost per LYG
was 39,463/62,744 SEK. Sub-analysis of PROVE-IT at 4 months
after ACS showed that cost per standardized event avoided using
A80 as acute therapy decreased to 20,270 SEK due to signiﬁ-
cantly fewer events in the A80 arm (171 compared to 212) and
minimal difference in total costs (A80/P40 event acute cost was
11,087,967/13,792,349 SEK and average total cost per patient
was 7,336/6,930 SEK). CONCLUSION: Secondary prevention
treatment using intensive lipid lowering therapy with A80 is a
highly cost-effective alternative to treatment with P40 in Sweden.
The cost per event avoided and cost per LYG is well within
acceptable threshold levels.
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OBJECTIVES: Nebivolol was demonstrated to be clinically
effective in patients with chronic heart failure (CHF) in the
SENIORS, the trial mirroring the real life CHF population. The
aim of this analysis is to assess the cost effectiveness of nebivolol
compared with standard treatment in elderly patients with heart
failure. METHODS: An individual patient simulation model,
based on a Markov modeling framework, was developed to
estimate life time costs and quality adjusted life years (QALYs)
for patients starting treatment at the age of 70. The model
consisted of ﬁve health states deﬁned by NYHA class and death.
Patient faced different risks of cardiovascular events or death.
The risk of each event in a given cycle was based on patients’
baseline characteristics and time on treatments. Input data for
the model were populated using individual patient data from the
SENIORS trial. Sensitivity analysis explored the implications of
different starting treatment cohort groups and lengths of treat-
ment beneﬁt. Internal validation compared model and trial based
results for different durations of treatment. RESULTS: In the
base case analysis, the total cost per patient was 4568 and
6287; mean life-years were 7.547 and 8.378; and QALYs were
5.2 and 5.844 over life time for patients aged 70 at starting of
treatment for the standard treatment and nebivolol groups
respectively. The probabilistic sensitivity analysis provided the
incremental cost effectiveness ratio was 2069 (95% CI 1947 to
2217)) per life year, and 2670 (95% CI 2475 to 2918) per
QALY. CONCLUSION: This analysis indicates that nebivolol is
highly cost-effective treatment for elderly patients with heart
failure compared to placebo. Strengths of our analysis included
being based on individual patient simulation, extending the
Markov modeling framework to enable the risk of events to be
varied over time.
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OBJECTIVES: Following HFR, deep vein thrombosis (DVT) and
pulmonary embolism (PE) are venous thromboembolic events
(VTE) associated with increased costs. Effectiveness of thrombo-
prophylactic strategies (TS) vary. Our objective was to compare
TS used in HFR for VTE outcomes and cost effectiveness (CE),
from the Veterans Affairs (VA) perspective. Comparative CE of
fondaparinux was assessed, using outcomes from clinical trials
and estimated costs from VA data. METHODS: Using retrospec-
tive, nationwide VA data; TS used among HFR patients (3/1/
2003 to 2/29/2004) were documented. We identiﬁed VTEs using
International Classiﬁcation of Disease, Version 9 codes. VA costs
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